Get access

Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia

Authors


  • Consensus meeting date and panel members:

    18 January 2004, Hong Kong

    S. Bavonratanavech (Thailand), H. Choi (South Korea), P. Delmas (France), R. Handa (India), E.M.C. Lau (China), J.K. Lee (Malaysia), KH Leong (Singapore), P.C. Leung (China), X.W. Meng (China), H. Morii (Japan), P. Sambrook (Australia), E. Seeman (Australia), S. Siribaddana (Sri Lanka), T Torralba (Philippines)

    Note: These guidelines are based mainly on the consensus discussion held in Hong Kong in January 2004. Some key research findings published after that date were added by members of the writing group.

: Dr Edith M. C. Lau, Hong Kong Orthopaedic and Osteoporosis Center for Treatment and Research, Unit 1301, Hing Wai Building, 36 Queen's Road Central, Hong Kong. Email: Edithmclau@netvigator.com

Abstract

According to the World Health Organization criteria, osteoporosis can be defined as a bone mineral density of −2.5 or more. Dual X-ray densitometry is the recognised method for diagnosing osteoporosis. Drugs which have been shown to be efficacious in treating osteoporosis include alendronate, residronate, ibandronate, raloxifene, teriparitide and strontium ranleate. Patients with established osteoporosis should be treated. Primary prevention of osteoporosis is important at the community level.

Get access to the full text of this article

Ancillary